• screen 1

     

    Oxygen Biotherapeutics

    Oxygen Biotherapeutics is a specialty pharmaceutical company focused on the development and commercialization of products for critical care patients

     

     

  • screen 2

    Levosimendan Development

    Levosimendan is under development in North America for reduction in morbidity and mortality of cardiac surgery patients at risk of low cardiac output syndrome (LCOS).

     

    img

  • screen 2

    Oxycyte® Development

    We are conducting Phase 2b clinical trials in Switzerland and Israel with our Oxycyte PFC emulsion.

    We also supply Oxycyte PFC emulsion to the US Navy for their ongoing preclinical research exploring the potential of using Oxycyte for the treatment of decompression sickness.

    img

Oxygen Biotherapeutics

Oxygen Biotherapeutics is a specialty pharmaceutical company focused on the development and commercialization of products for critical care patients

Product Pipeline

Currently, we have two product candidates. Levosimendan is being developed for use in cardiac surgery patients at risk of Low Cardiac Output Syndrome (LCOS). Oxycyte PFC emulsion, is being developed to treat patients with traumatic brain injury (TBI). more...

Clinical Trials

Oxygen Biotherapeutics’ clinical development is supported by significant preclinical and clinical research. more...

Oxygen Biotherapeutics Announces Fiscal Year 2014 Financial Results

 

• Acquired strategic assets from Phyxius Pharma, including lead candidate levosimendan; named John Kelley as CEO

• Activated sites for Phase 3 LEVO-CTS trial for levosimendan in LCOS in the U.S., with data expected in first calendar quarter of 2016

• Raised $55.0 million in net proceeds through secondary offering in March 2014
Conference call today at 8:30am ET


Tuesday, July 29, 2014 8:00 am EDT
Dateline:
MORRISVILLE, N.C.

Public Company Information:
NASDAQ:OXBT US69207P2092


MORRISVILLE, N.C.--(BUSINESS WIRE)--Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT) a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market, today announced financial results for the fiscal year ended April 30, 2014, and provided a corporate update. more..

Quick Links

Product Pipeline Development

Levosimendan- Phase 3

Levosimendan is under development in North America for reduction in morbidity and mortality of cardiac surgery patients at risk of low cardiac output syndrome (LCOS). The FDA has granted Fast Track status for levosimendan and has agreed to our Phase 3 clinical trial protocol under a Special Protocol Assessment (SPA). The FDA has provided guidance that a single successful trial will be sufficient to support approval of levosimendan in this indication.  Learn more...

Oxycyte® – Phase 2

Phase 1 and 2a clinical development studies were conducted in the United States. The ongoing clinical trial in traumatic brain injury (TBI) is a double-blind, placebo–controlled, dose-escalation study. The first cohort of patients has been successfully completed in Israel and Switzerland with an independent data safety monitoring board approving advancement to the next higher dose. Enrollment in the second cohort, which began in May 2013, is progressing. On February 28, 2014, following submissions of animal data to address the FDA’s prior clinical hold, the FDA announced in a meeting with the Company that we have satisfactorily addressed their safety concerns. The clinical hold was formally lifted on March 7, 2014 when we received written confirmation from the FDA”.  Learn more...